我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 guangzhou hedy group co. ltd.
相关临床试验
9
7 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2003
进行中（未招募）
7
77.8%
已完成
1
11.1%
招募中
暂无批准数据
- Hikma Pharmaceuticals launched STARJEMZA (ustekinumab-hmny) on November 6, 2025, marking the company's first biosimilar entry into the US market. - The biosimilar references Janssen's STELARA and is approved for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. - STARJEMZA became the seventh ustekinumab biosimilar to receive FDA approval on May 22, 2025, developed by Bio-Thera under a 2021 partnership agreement. - The launch represents a significant milestone for Hikma's biosimilar strategy and adds another treatment option for patients with inflammatory conditions.
